Last reviewed 2026-04-19 · How we verify

Cethrin

Vertex Pharmaceuticals Incorporated · Phase 1 active Small molecule

Cethrin is a Small molecule drug developed by Vertex Pharmaceuticals Incorporated. It is currently in Phase 1 development. Also known as: (BA-210).

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Vertex Pharmaceuticals Incorporated is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Cethrin
Also known as	(BA-210)
Sponsor	Vertex Pharmaceuticals Incorporated
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries (PHASE1, PHASE2)
Cethrin in Acute Cervical Spinal Cord Injury (PHASE2, PHASE3)
Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cethrin CI brief — competitive landscape report
Cethrin updates RSS · CI watch RSS
Vertex Pharmaceuticals Incorporated portfolio CI

Frequently asked questions about Cethrin

What is Cethrin?

Cethrin is a Small molecule drug developed by Vertex Pharmaceuticals Incorporated.

Who makes Cethrin?

Cethrin is developed by Vertex Pharmaceuticals Incorporated (see full Vertex Pharmaceuticals Incorporated pipeline at /company/vertex-pharmaceuticals-incorporated).

Is Cethrin also known as anything else?

Cethrin is also known as (BA-210).

What development phase is Cethrin in?

Cethrin is in Phase 1.

Manufacturer: Vertex Pharmaceuticals Incorporated — full pipeline
Therapeutic area: All drugs in Other
Also known as: (BA-210)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing